Keywords
Last Name
Institution

John O. Mascarenhas

TitleASSISTANT PROFESSOR
InstitutionMount Sinai
DepartmentMedicine
Address1470 Madison Avenue
3rd floor
New York NY 10029
Phone212-241-6756

     Bibliographic 
     selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Mascarenhas JO, Orazi A, Bhalla KN, Champlin RE, Harrison C, Hoffman R. Advances in myelofibrosis: a clinical case approach. Haematologica. 2013 Oct; 98(10):1499-509.
      View in: PubMed
    2. Kremyanskaya M, Atallah EL, Hoffman R, Mascarenhas JO. Clarifying the use of ruxolitinib in patients with myelofibrosis. Oncology (Williston Park). 2013 Jul; 27(7):706-14.
      View in: PubMed
    3. Mascarenhas J, Hoffman R. A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis. Blood. 2013 Jun 13; 121(24):4832-7.
      View in: PubMed
    4. Mascarenhas J, Lu M, Li T, Petersen B, Hochman T, Najfeld V, Goldberg JD, Hoffman R. A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF). Br J Haematol. 2013 Apr; 161(1):68-75.
      View in: PubMed
    5. Ragupathi L, Najfeld V, Chari A, Petersen B, Jagannath S, Mascarenhas J. A case report of chronic myelogenous leukemia in a patient with multiple myeloma and a review of the literature. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):175-9.
      View in: PubMed
    6. Mascarenhas J, Heaney ML, Najfeld V, Hexner E, Abdel-Wahab O, Rampal R, Ravandi F, Petersen B, Roboz G, Feldman E, Podoltsev N, Douer D, Levine R, Tallman M, Hoffman R. Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium. Leuk Res. 2012 Dec; 36(12):1500-4.
      View in: PubMed
    7. Lu M, Wang X, Li Y, Tripodi J, Mosoyan G, Mascarenhas J, Kremyanskaya M, Najfeld V, Hoffman R. Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-a 2a specifically targets JAK2V617F-positive polycythemia vera cells. Blood. 2012 Oct 11; 120(15):3098-105.
      View in: PubMed
    8. Cotter R, Najfeld V, Isola L, Del Toro G, Roman E, Petersen B, Mascarenhas J. An unusual case of donor-derived myelodysplastic syndrome following double-unit umbilical cord blood transplantation in acute lymphoblastic leukemia. Am J Hematol. 2012 Sep; 87(9):931-3.
      View in: PubMed
    9. Mascarenhas J, Hoffman R. Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. Clin Cancer Res. 2012 Jun 1; 18(11):3008-14.
      View in: PubMed
    10. Kremyanskaya M, Mascarenhas J, Hoffman R. Why does my patient have erythrocytosis? Hematol Oncol Clin North Am. 2012 Apr; 26(2):267-83, vii-viii.
      View in: PubMed
    11. Iancu-Rubin C, Gajzer D, Mosoyan G, Feller F, Mascarenhas J, Hoffman R. Panobinostat (LBH589)-induced acetylation of tubulin impairs megakaryocyte maturation and platelet formation. Exp Hematol. 2012 Jul; 40(7):564-74.
      View in: PubMed
    12. Mascarenhas J, Mughal TI, Verstovsek S. Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib. Curr Med Chem. 2012; 19(26):4399-413.
      View in: PubMed
    13. Najfeld V, Wisch N, Mascarenhas J, Issa L, Tripodi J, Sidhu M, Hoffman R. Development of t(8;21) and RUNX1-RUNX1T1 in the Philadelphia-positive clone of a patient with chronic myelogenous leukemia: additional evidence for multiple steps involved in disease progression. Cancer Genet. 2011 Mar; 204(3):165-70.
      View in: PubMed
    14. Mascarenhas J, Hoffman R. Myeloproliferative neoplasms: new translational therapies. Mt Sinai J Med. 2010 Nov-Dec; 77(6):667-83.
      View in: PubMed
    15. Mascarenhas J, Navada S, Malone A, Rodriguez A, Najfeld V, Hoffman R. Therapeutic options for patients with myelofibrosis in blast phase. Leuk Res. 2010 Sep; 34(9):1246-9.
      View in: PubMed
    16. Lu M, Wang J, Li Y, Berenzon D, Wang X, Mascarenhas J, Xu M, Hoffman R. Treatment with the Bcl-xL inhibitor ABT-737 in combination with interferon a specifically targets JAK2V617F-positive polycythemia vera hematopoietic progenitor cells. Blood. 2010 Nov 18; 116(20):4284-7.
      View in: PubMed
    17. Cho SY, Xu M, Roboz J, Lu M, Mascarenhas J, Hoffman R. The effect of CXCL12 processing on CD34+ cell migration in myeloproliferative neoplasms. Cancer Res. 2010 Apr 15; 70(8):3402-10.
      View in: PubMed
    18. Lu M, Zhang W, Li Y, Berenzon D, Wang X, Wang J, Mascarenhas J, Xu M, Hoffman R. Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway. Exp Hematol. 2010 Jun; 38(6):472-80.
      View in: PubMed
    19. Sozer S, Fiel MI, Schiano T, Xu M, Mascarenhas J, Hoffman R. The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood. 2009 May 21; 113(21):5246-9.
      View in: PubMed
    20. Ishii T, Wang J, Zhang W, Mascarenhas J, Hoffman R, Dai Y, Wisch N, Xu M. Pivotal role of mast cells in pruritogenesis in patients with myeloproliferative disorders. Blood. 2009 Jun 4; 113(23):5942-50.
      View in: PubMed
    21. Webber NP, Mascarenhas JO, Crow MK, Bussel J, Schattner EJ. Functional properties of lymphocytes in idiopathic thrombocytopenic purpura. Hum Immunol. 2001 Dec; 62(12):1346-55.
      View in: PubMed
    22. Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol. 2000 Feb 15; 164(4):2200-6.
      View in: PubMed
    Mascarenhas's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts
    _
    Co-Authors
    _
    Similar People
    _
    Same Department
     
    Mount Sinai Profiles is managed by Conduits - The Institutes for Translational Sciences at Icahn School of Medicine, supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences of the National Institutes of Health through Grant Number UL1TR000067